RapidAI Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
189
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$25M
- Investors
-
2
RapidAI General Information
Description
Operator of neuroimaging platform intended to create high-quality images from non-contrast CT and MRI scans. The company's platform provides viewing, processing, and analysis of brain images and also empowers clinicians to make accurate diagnostic and treatment decisions for stroke patients, enabling doctors to get additional assistance while treating strokes.
Contact Information
Website
www.rapidai.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Primary Office
- 1120 Washington Avenue
- Suite 200
- Golden, CO 80401
- United States
+1 (650) 000-0000
RapidAI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 16-Sep-2020 | $25M | 0000 | 00000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 10-Jan-2014 | 000 | 000 | 0000 | Completed | Generating Revenue |
RapidAI Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
RapidAI Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RapidAI Patents
RapidAI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230036757-A1 | Concurrent display of hemodynamic parameters and damaged brain tissue | Pending | 28-Jul-2021 | 000000000 | |
| US-11295448-B1 | Concurrent display of hemodynamic parameters and damaged brain tissue | Active | 28-Jul-2021 | 000000000 | 0 |
| US-11348241-B2 | Identifying vessel occlusions using spatial patterns | Active | 14-Oct-2020 | 0000000000 | 0 |
| US-20220114726-A1 | Identifying vessel occlusions using spatial patterns | Active | 14-Oct-2020 | 0000000000 | |
| EP-4142580-A1 | Assessment of facial paralysis and gaze deviation | Pending | 29-Apr-2020 | A61B5/163 |
RapidAI Executive Team (12)
RapidAI Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Erol Dervis | Lennertz & Co. | Board Member | 000 0000 |
| Gregory Albers MD | RapidAI | Co-Founder, Scientific Lead & Chairman | 000 0000 |
| Hadi Saleh Ph.D | Self | Board Observer | 000 0000 |
| John Drew | Self | Board Member | 000 0000 |
| Karim Karti | Self | Chief Executive Officer & Board Member | 000 0000 |
RapidAI Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
RapidAI Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Lennertz & Co. | Family Office | Minority | 000 0000 | 000000 0 | |
| Listwin Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
RapidAI Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 | 09-Jun-2020 | 0000000000 | Other Devices and Supplies | 000000 00 |